Detalhe da pesquisa
1.
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
Clin Gastroenterol Hepatol;
21(10): 2616-2628.e7, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36623678
2.
A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6+ T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation.
J Pharmacol Exp Ther;
386(1): 80-92, 2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37142443
3.
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
Br J Dermatol;
189(1): 33-41, 2023 07 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36972293
4.
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
J Am Acad Dermatol;
88(2): 395-403, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36370907
5.
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
J Allergy Clin Immunol;
149(4): 1318-1328, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34863853
6.
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.
Br J Dermatol;
187(6): 878-887, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35986699
7.
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.
J Am Acad Dermatol;
87(2): 333-342, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35398218
8.
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.
Clin Gastroenterol Hepatol;
19(11): 2324-2332.e6, 2021 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34126262
9.
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
J Am Acad Dermatol;
85(2): 379-387, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33757798
10.
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
Ann Rheum Dis;
76(3): 534-542, 2017 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27672124
11.
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development.
Drug Discov Today;
29(5): 103948, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38460567
12.
Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial.
JAMA Dermatol;
160(2): 156-163, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38117526
13.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study.
J Clin Pharmacol;
2023 Sep 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37772436
14.
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
Arthritis Rheumatol;
75(8): 1370-1380, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37194394
15.
Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial.
JID Innov;
2(6): 100156, 2022 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36277481
16.
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.
Inflamm Bowel Dis;
28(3): 434-446, 2022 03 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34427649
17.
Reviving an R&D pipeline: a step change in the Phase II success rate.
Drug Discov Today;
26(2): 308-314, 2021 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33129994
18.
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
Clin Transl Sci;
14(2): 671-682, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33290616
19.
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Arthritis Rheumatol;
73(7): 1155-1166, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33455090
20.
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.
Lancet Rheumatol;
3(3): e204-e213, 2021 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38279383